Skip to main content

Journals in Drug discovery

10 results in All results

Artificial Intelligence in the Life Sciences

  • ISSN: 2667-3185
Providing a scientific forum for practical applications and theoretical advances of Artificial Intelligence (AI) in the life sciences and related disciplines including (but not restricted to): General, molecular, and systems biology Population and disease genetics Medicinal chemistry and chemical biology Pharmacology and drug discovery Epidemiology and clinical investigations Background: Artificial Intelligence originates from computer science and covers a wide range of approaches intended to enhance the ability of machines to make data-driven decisions and accurate predictions of events. In many scientific fields, AI is being increasingly considered and integrated, especially in the context of Big Data. Given their complexity and highly interdisciplinary nature, the life sciences provide ample opportunities for AI to impact R&D efforts in a variety of ways. Key words: Artificial Intelligence; Life Sciences; Drug Discovery; Bio- and Cheminformatics, Machine Learning; Machine Intelligence; Deep Learning; Data Mining; Big Data.
Artificial Intelligence in the Life Sciences

Drug Discovery Today

  • ISSN: 1359-6446
  • 5 Year impact factor: 8.1
  • Impact factor: 7.4
Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports. Coverage includes: • Novel therapeutic strategies • High-throughput screening • Therapeutic targets • Combinatorial chemistry, parallel synthesis and library design • Drug delivery • ADME/Tox • Advances in key compound classes and therapeutic areas • Genomics and proteomics • Automation and technology • Virtual chemistry • Informatics • Business strategy • Clinical trials and other aspects of drug discovery. Ethics in Publishing: General Statement The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict. For more information, please refer to: https://www.elsevier.com/conflictsofinterest Submission to Drug Discovery Today is by invitation only. If you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. Information on how to submit a proposal can be found at: http://www.drugdiscoverytoday.com/submit-a-paper/
Drug Discovery Today

Heliyon

  • ISSN: 2405-8440
  • 5 Year impact factor: 4.1
  • Impact factor: 4
Heliyon is an all-science, open access journal that is part of the Cell Press family. Any paper reporting scientifically accurate and valuable research, which adheres to accepted ethical and scientific publishing standards, will be considered for publication. As such, the journal also publishes manuscripts reporting negative/null results, incremental advances, and replication studies. Dedicated section editors, associate editors, and our in-house team handle your manuscript and manage the publication process end to end, giving your research the editorial support it deserves. If it's important to you, it's important to us. Submit your paper today.
Heliyon

Journal of Holistic Integrative Pharmacy

  • ISSN: 2707-3688
Journal of Holistic Integrative Pharmacy is an open-access journal, officially sponsored by Guangdong Pharmaceutical University and China Institute for Development Strategy of Holistic Integrative Medicine. With the aim of promoting academic exchanges and disciplinary development of pharmaceutical sciences, this journal provides an important platform for the communication of holistic integrative pharmacy and its related disciplines. Spanning all aspects in the integration of various relevant disciplines of pharmaceutical sciences, such as the combination of pharmacy with traditional medicine, pharmacy with modern medicine, pharmacy with modern new technology, basic pharmaceutical research with application and development, pharmacy with humanities, etc. This journal publishes a range of article types, including highlights, reviews, and original research.
Journal of Holistic Integrative Pharmacy

Medicine in Drug Discovery

  • ISSN: 2590-0986
Medicine in Drug Discovery is a peer-reviewed open access journal. The journal publishes original papers related to basic, preclinical and clinical studies covering all aspects of drug discovery and development. Clinical studies with a focus on efficacy and safety, target engagement, biomarkers, PK/PD, side effects etc. are also covered in the journal. Article types accepted include, but are not limited to, original research articles, reviews, case reports, short communications and editorials. The journal is in cooperation with The National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences. Benefits to authors We provide many author benefits, such as APC waivers for accepted manuscripts submitted by 31 December 2020, certificate of publication for your article and much more. Please click here for more information on our author services. Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center.
Medicine in Drug Discovery

Next Research

  • ISSN: 3050-4759
Next Research is a peer-reviewed multidisciplinary journal, publishing research spanning all scientific technical and medical communities. The journal is part of the Next family, a new suite of multidisciplinary journals from Elsevier spanning all branches of science. Managed by our dedicated team of in-house Editors, Next Research offers authors speed, consistency, innovation, flexibility, and ease of submission. Next Research is an inclusive venue for scientifically accurate manuscripts that meet the ethical and scientific publishing standards. It publishes all research topics across the fields of health sciences, physical sciences, life sciences and social sciences. Next Research publishes experimental, computational, and theoretical work, in traditional formats such as Original Research Articles, Communications and Reviews, as well as novel formats and video content. The journal provides authors with rigorous peer review ensuring articles adhere to a high technical standard, with rapid decisions and a highly visible platform for scientists to share their research. We believe that all rigorous research should be shared.
Next Research

Organs-on-a-Chip

  • ISSN: 2666-1020
Organs-on-a-Chip is an interdisciplinary open access journal dedicated to publishing research and development in the field of organs, tissues and organoids on chips and their application. The journal aims to promote original works on microphysiological systems that demonstrate significant progress beyond the current state-of-the-art in these fields, along with applicability to solve meaningful problems. Organs-on-a-Chip will publish works that are supported by experimental results, and as such purely theoretical works will not be accepted. The scope of the journal encompasses, but is not restricted to, the following areas: Novel applications Development and characterization of OOC/TOC platforms Fabrication technology Tissue on a chip Organoid applications on/off chip
Organs-on-a-Chip

Phytomedicine

  • ISSN: 0944-7113
  • 5 Year impact factor: 6.8
  • Impact factor: 7.9
International Journal of Phytotherapy and PhytopharmacologyPublished in affiliation with the European Scientific Cooperative On Phytotherapy (ESCOP) Phytomedicine is primarily a therapy-oriented Journal. Phytomedicine publishes innovative studies on efficacy, safety, quality and mechanisms of action of specified plant extracts, phytopharmaceuticals and their isolated constituents. This includes clinical, pharmacological, pharmacokinetic, and toxicological studies of specified herbal medicinal products, herbal preparations and purified compounds which have a defined and consistent quality assuring reproducible pharmacological activity. Phytomedicine was founded in 1994 to focus and stimulate research in this particular field and to set internationally accepted scientific standards for pharmacological studies, proof of clinical efficacy and safety of phytomedicines. The main aims of Phytomedicine are associated with the integration of phytopreparations into conventional/official medicine. The journal covers the following sections: Clinical pharmacology and toxicology (randomized, placebo controlled, double blind, and observational open label studies) Behavioural, mental, affective, and stress-associated disorders Age-associated disorders Neuropharmacology Endocrine pharmacology Metabolic syndrome and obesity Cancer Immunopharmacology, inflammation Infectious diseases Pulmonary, gastrointestinal, cardiovascular and urogenital diseases Systems biology Safety assessment, pre-clinical toxicology, interaction with drugs and adverse events of herbal preparations Pharmacokinetic of natural compounds Standardization of herbal preparations Legislation of botanicals Invited reviews The directions of Phytomedicine are known to provide profound scientific background in Herbal Medicinal Products, their reproducible Quality and evidence based therapeutic efficacy. Since then quality criteria and standardization methods were defined and the European Medical Agency has elaborated numerous guidelines for the conduction of clinical studies and preparation of Herbal Medicinal Products. In total 107 ESCOP monographs have been produced and submitted to EMA. Many new analytical methods and instruments were implemented both for analysis and standardization of herbal Substances, herbal preparations and their bioassays and tremendous work has been carried out to remain aligned with these intentions during the last 18 years. Nowadays important topics remain to be approached, such as harmonization of the regulatory frameworks in Europe, America, Asia and Australia or the legislation of various "botanicals", where strict differentiation of requirements for health claims of herbal medicinal product, dietary supplements and nutraceuticals are required. Phytomedicine is the companion title to the open access journal Phytomedicine Plus.
Phytomedicine

SLAS Discovery

  • ISSN: 2472-5552
Advancing the Science of Drug DiscoveryAn official journal of SLAS SLAS Discovery reports how scientists develop and use novel technologies and/or approaches to provide and characterize chemical and biological tools to understand and treat human disease. The journal focuses on drug discovery sciences with a strong record of scientific rigor and impact, reporting on research that: Enables and improves target validation Evaluates current drug discovery technologies Provides novel research tools Incorporates research approaches that enhance depth of knowledge and drug Discovery success SLAS Discovery's Editorial Scope Includes: scientific and technical advances in target identification/validation (including chemical probes, RNA silencing, gene editing technologies); biomarker discovery; assay development; virtual, medium- or high-throughput screening (biochemical and biological, biophysical, phenotypic, toxicological, ADME); lead generation/optimization; chemical biology; and informatics (data analysis, image analysis, statistics, bio- and chemo-informatics). Review articles cover new paradigms in drug discovery and advances in drug discovery technologies. SLAS Discovery is of particular interest to those involved in analytical chemistry, applied microbiology, automation, biochemistry, bioengineering, biomedical optics, biotechnology, bioinformatics, cell biology, DNA science and technology, genetics, information technology, medicinal chemistry, molecular biology, natural products chemistry, organic chemistry, pharmacology, spectroscopy, and toxicology.
SLAS Discovery

Translational Proteomics

  • ISSN: 2212-9626
Translational Proteomics covers all areas of human proteomics using multi-disciplinary approaches to untangle complex disease processes. Emphasis is placed on linking basic sciences to clinical research (from patient to bench to bedside). It focuses on the rapid dissemination of novel discoveries. Topics included but not limited to are: Translational Systems Biology and Integrative Bioinformatics Clinical Proteomics and Personalized medicine Comparative proteomics and drug development Medical bioinformatics and biostatistics Biomarkers Food and Health Translational Proteomics is intended to academic, industrial and clinical researchers, physicians, pharmaceutical scientists, biochemists, clinical chemists, disease molecular biologists in the fields of applied human proteomics. Examples of diseases include oncology, neurology, immunity, cardiovascular disease, infectious diseases and any internal medicine disorder.
Translational Proteomics